Kidney tumor ablation: does it destroy cancer and boost well-being?
NCT ID NCT01888198
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tracks people who have had or will have a procedure called ablation to destroy kidney tumors. Researchers want to see how effective the procedure is and whether it improves patients' quality of life. Participants fill out questionnaires about their health and well-being. The goal is to learn which ablation techniques work best for different types of kidney masses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors choose the best ablation technique to improve both tumor control and quality of life for kidney cancer patients.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tazemetostat Expanded Access for Solid Tumors NCT03874455
- Cadonilimab & Axitinib for Advanced Kidney Cance NCT05256472
- LAYOVER Trial: Ablative Therapy for Oligo-Progre NCT06101290
- TRK-950 Combination Therapy for Advanced Solid T NCT03872947
- IMEPOCA Study: Nivolumab Fixed vs Weight-Based D NCT05380336
- Study of Double-Positive Cells in Metastatic Can NCT06967961
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States